Related Experiment Video
Updated: Apr 21, 2026
Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
Mdm2 and p53 Expression in Radiation-Induced Sarcomas of the Head and Neck: Comparison with De Novo Sarcomas
Min Jeong Song1, Joon Seon Song1, Jong-Lyel Roh2
1Departments of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Background:
The pathogenesis of radiation-induced sarcomas (RISs) is not well known. In RIS, TP53 mutations are frequent, but little is known about Mdm2-p53 interaction, which is a recent therapeutic target of sarcomas.
Methods:
We studied the immunohistochemical expression of Mdm2 and p53 of 8 RISs. The intervals between radiation therapy and diagnosis of secondary sarcomas ranged from 3 to 17 years.
Results:
Mdm2 expression was more common in de novo sarcomas than RISs (75% vs 37.5%), and p53 expression was more common in RISs than in de novo cases (75% vs 37.5%). While half of the RISs were Mdm2(-)/p53(+), none of de novo cases showed such combination; while half of de novo sarcomas were Mdm2(+)/p53(-), which are a candidate group of Mdm2 inhibitors, only 1 RIS showed such a combination. Variable immunoprofiles observed in both groups did not correlate with tumor types, except that all of 2 myxofibrosarcomas were Mdm2(+)/p53(+).
Conclusions:
In conclusion, we speculated that both radiation-induced and de novo sarcomagenesis are not due to a unique genetic mechanism. Mdm2-expression without p53 overexpression in 1 case of RIS decreases the future possibility of applying Mdm2 inhibitors on a subset of these difficult tumors.
Insights
The study found distinct Mdm2 and p53 expression patterns in radiation-induced sarcomas (RISs) compared to de novo sarcomas. This suggests different genetic mechanisms and impacts potential Mdm2 inhibitor therapies for RIS.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The origins of radiation-induced sarcomas (RISs) are unclear, though TP53 mutations are common.
- The Mdm2-p53 interaction is a key pathway in sarcomas and a potential therapeutic target.
Purpose of the Study:
- To investigate the immunohistochemical expression of Mdm2 and p53 in radiation-induced sarcomas (RISs).
- To compare Mdm2 and p53 expression profiles between RISs and de novo sarcomas.
- To assess the implications for Mdm2 inhibitor therapy in RIS.
Main Methods:
- Immunohistochemical analysis of Mdm2 and p53 expression in 8 RIS samples.
- Comparison of expression patterns with de novo sarcoma cases.
- Correlation of immunoprofiles with tumor types and clinical data.
Main Results:
- RISs showed higher p53 expression (75%) compared to de novo sarcomas (37.5%).
- De novo sarcomas had more Mdm2 expression (75%) than RISs (37.5%).
- Distinct Mdm2/p53 combinations were observed, with only one RIS case showing Mdm2 expression without p53 overexpression.
Conclusions:
- Radiation-induced and de novo sarcomagenesis likely involve different genetic pathways.
- The presence of Mdm2 expression without p53 overexpression in some RIS cases may limit the efficacy of Mdm2 inhibitors.
Related Concept Videos
02:23Abnormal Proliferation
02:36DNA Damage can Stall the Cell Cycle
02:36DNA Damage Can Stall the Cell Cycle